DURAMED PHARMS BARR
GenericsDURAMED PHARMS BARR is a generic drug manufacturer focused on Cardiovascular, Neurology, Dermatology.
DURAMED PHARMS BARR's Key Drugs
DURAMED PHARMS BARR's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
DURAMED PHARMS BARR's Recent FDA Approvals
New NDA/BLA approvals for DURAMED PHARMS BARR over the last two years — novel drugs only, excluding generics and label supplements.
DURAMED PHARMS BARR's Therapeutic Areas
DURAMED PHARMS BARR's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
DURAMED PHARMS BARR's Top Competitors
DURAMED PHARMS BARR's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PAI HOLDINGS PHARM, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
DURAMED PHARMS BARR Pipeline Snapshot
Active clinical trials for DURAMED PHARMS BARR across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1983-03-17
- Latest
- 2024-05-31
- Applications
- 68